- Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026 and a PMA process expected to begin by the end of 2027.
- FDA approved a single-arm protocol using a historical microfracture control data package the company owns, and Regentis reports that the first 40 patients closely match that control group.
- In Europe, where GelrinC already holds CE Mark approval, surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network and a newly approved manufacturing process that raises yield approximately 400%.
For development-stage medical technology companies, regulatory approval and commercial revenue often sit years apart. A trial needs to be finished, a submission must clear review, manufacturing has to scale, surgeons must be trained and distribution has to be built. Companies able to run those workstreams in parallel rather than in sequence compress the distance between clinical validation and market adoption. Regentis Biomaterials (NYSE American: RGNT) is attempting exactly that, advancing its GelrinC(R) cartilage repair platform along a U.S. clinical track and a European commercial track and scaling of manufacturing at the same time.
The U.S. Program Approaches Its Defining Milestone
GelrinC is a cell-free, off-the-shelf hydrogel implant for focal articular cartilage defects in the knee. Rather than harvesting cells from the patient, expanding them in a laboratory and implanting them during a second surgery, GelrinC arrives ready to use and is implanted in a procedure lasting roughly 10 minutes. The hydrogel forms a temporary programmed matrix inside the defect, then erodes on a synchronized schedule as surrounding cells aggregate and form new tissue inward.
The pivotal SAGE study is enrolling 80 patients under an FDA-approved IDE protocol running across the U.S., Europe and Israel. More than half of the targeted 80 patients have been recruited and treated, with the study incorporating 24-month follow-up. The company reports no serious adverse events observed to date. Regentis is targeting completion of recruitment in the third quarter of 2026, with a premarket approval submission expected to begin at the end of 2027.
Completing enrollment would move the program out of patient recruitment and into data generation, the phase that produces the package a PMA filing rests on.
A Protocol Designed to Reduce Trial Risk
The study design merits attention on its own. FDA permitted a single-arm protocol using a historical microfracture control data package owned by Regentis and drawn from the TiGenix NV1 program, rather than requiring a concurrent randomized control arm. That design reduces the cost and variability associated with recruiting and managing a concurrent control cohort.
It also provides an early read on comparability. According to the company, the first 40 patients closely match the historical control group in baseline characteristics, an important consideration validating the comparability of the two populations.
The clinical foundation beneath that design came from a 56-patient Phase II study followed for up to five years in Northern Europe and Israel. Primary endpoints were met at 24 months, with approximately 100% greater KOOS pain and function improvement compared to microfracture and a mean MOCART imaging score of 88.8 out of 100, providing additional objective and quantitative evidence of quantity and quality of cartilage repair.
Europe Shifts from Approval to Adoption
Europe sits further along because GelrinC has already secured CE Mark approval. The focus there can therefore shift from obtaining initial authorization toward commercialization, surgeon adoption and distribution.
Hands-on surgeon training begins in the third quarter of 2026 at Humanitas Research Hospital in Milan, with additional sessions planned for other major European markets. Those sessions anchor a growing network of European Centers of Excellence intended to function as clinical hubs were experienced orthopedic surgeons train and support other physicians. The clinical site network behind that effort has expanded beyond Northern and Central Europe into Italy and Eastern Europe, adding sites in Pavia, Hamburg, Ljubljana, Timisoara and Belgrade.
On the commercial side, Regentis has been exploring regional distributors to map country priorities and working with European toll manufacturers on commercial sourcing.
Supply Built Ahead of Demand
Manufacturing is the piece that can stall a launch. In July, the European Notified Body approved the company’s next-generation solvent-free process for GelrinC, which Regentis says increases production yield by approximately 400%, or roughly fivefold, from the same manufacturing volume while lowering cost and improving occupational and environmental safety.
The timing may be as important as the magnitude of the improvement. Regentis can enter European commercialization using the higher-yield process.
Two Timelines, One Objective
The significance of the company’s current position lies in convergence rather than in any single announcement. In the United States, Regentis is progressing towards the enrollment milestone that opens the path toward a PMA filing. In Europe, approval is behind it and the remaining work is training, connecting with distributors and supply. Both tracks point at the same outcome: turning years of clinical development into a cartilage repair product that can be manufactured, sold and used on a scale.
NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT
This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai
RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN
Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
